View Valuation1CM 将来の成長Future 基準チェック /06現在、 1CMの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Tanvi Bhandari was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 081CM Inc. Announces Chief Financial Officer Changes, Effective January 7, 20261CM Inc. announced that its board of directors has appointed Antony Pramoth as Chief Financial Officer of the company. Mr. Pramoth succeeds Harshil Chovatiya, who has served as the Company's Chief Financial Officer since February 24, 2023, effective January 7, 2026. Mr. Pramoth has been with the company since October 2023. The company is promoted Mr. Pramoth to the role of CFO.お知らせ • Apr 231CM Inc., Annual General Meeting, Jun 16, 20251CM Inc., Annual General Meeting, Jun 16, 2025. Location: ontario, toronto Canadaお知らせ • Sep 261Cm Inc. Expands its Operations Adding Tobacco, CPG, Private Label Products1CM Inc. announce the addition of Tobacco, Vape & Consumer Packaged Goods products to its retail portfolio. 1CM has begun retailing cigarettes and vape products as an authorized retailer of Imperial Tobacco Canada Ltd. A wholly owned subsidiary of British American Tobacco and Rothmans Benson & Hedges Inc. A wholly owned subsidiary of Altria (formerly Philip Morris International). These products are purchased directly from the manufacturers. 1CM has further begun retailing complimentary CPG products from Pepsi, Frito-Lay, Parmalat & Canada Bread. The products are distributed to the company from Arctic Beverages. 1CM has also begun producing its private label Vodka and Vodka Iced Tea. Under the brand "EPIC MILFF". These products are manufactured in collaboration with Minhas Sask Ventures Inc. This strategic horizontal expansion marks a significant milestone for the 1CM as it now extends its operations to Tobacco, CPG and Private Label products. 1CM will continue to leverage its technology to warehouse, mine and obtain insights from the valuable data obtained from its retail customers of Cannabis, Liquor, Tobacco, & CPG products. This data will allow the company to determine channel complementarity and provide unique cross-channel marketing opportunities and experiences to the age-gated 1CM customers. In industries like Tobacco and Cannabis with strict regulations around marketing, this provides an invaluable resource to 1CM and the tobacco industry as they will have a compliant marketing opportunity, supported by high quality data on purchasing patterns across multiple channels. 1CM is building a reputation in the liquor retail industry for its commitment to exceptional customer service, and value. These new product offerings will improve the customer experience and increase revenues.お知らせ • Aug 011CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million.1CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million on December 1, 2022.1CM Inc. (CNSX:EPIC) completed the acquisition of Fresh Cannabis Co. Inc. from Cost Cannabis Inc. on December 1, 2022.Board Change • Sep 15High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Lucas Leone is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jan 29First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.012 loss per share (down from CA$0.011 loss in 1Q 2021). Revenue: CA$228.1k (up 313% from 1Q 2021). Net loss: CA$991.0k (loss widened 10% from 1Q 2021). Revenue was in line with analyst estimates.Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Is New 90 Day High Low • Mar 06New 90-day high: €0.37The company is up 215% from its price of €0.12 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Is New 90 Day High Low • Feb 11New 90-day high: €0.35The company is up 249% from its price of €0.099 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 22New 90-day high: €0.22The company is up 136% from its price of €0.095 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、1CM は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:IQ70 - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数2/28/202675422N/A11/30/202575122N/A8/31/202573023N/A5/31/202570236N/A2/28/202567234N/A11/30/202462124N/A8/31/202457112N/A5/31/202452-1-2-2N/A2/29/202446-1-5-2N/A11/30/202340-2-5-1N/A8/31/202335-1-4-2N/A5/31/202324-2-40N/A2/28/202315-3-2-2N/A11/30/20228-3-3-2N/A8/31/20221-5-3-3N/A5/31/20221-5-2-1N/A2/28/20221-5-1-1N/A11/30/20211-5-2-2N/A8/31/20210-5-2-2N/A5/31/20210-4-1-2N/A2/28/20210-3-2-2N/A11/30/20200-3-5-1N/A8/31/20200-3-6-2N/A5/31/20200-28-8-2N/A2/29/20200-28-7-3N/A11/30/20190-28N/A-3N/A8/31/20190-29N/A-3N/A5/31/20190-7N/A-3N/A2/28/20190-8N/A-2N/A11/30/20180-7N/A-2N/A8/31/20180-6N/A-1N/A5/31/20180-2N/A0N/A2/28/201800N/A0N/A11/30/2017N/A0N/A0N/A8/31/2017N/A0N/A0N/A5/31/2017N/A0N/A0N/A2/28/2017N/A0N/A0N/A11/30/2016N/A0N/A0N/A8/31/2016N/A0N/A0N/A5/31/2016N/A-1N/A0N/A2/29/2016N/A-1N/A0N/A11/30/2015N/A-1N/A0N/A8/31/2015N/A-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IQ70の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: IQ70の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: IQ70の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: IQ70の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: IQ70の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IQ70の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 21:08終値2026/05/22 00:00収益2026/02/28年間収益2025/08/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋1CM Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Tanvi Bhandari was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 081CM Inc. Announces Chief Financial Officer Changes, Effective January 7, 20261CM Inc. announced that its board of directors has appointed Antony Pramoth as Chief Financial Officer of the company. Mr. Pramoth succeeds Harshil Chovatiya, who has served as the Company's Chief Financial Officer since February 24, 2023, effective January 7, 2026. Mr. Pramoth has been with the company since October 2023. The company is promoted Mr. Pramoth to the role of CFO.
お知らせ • Apr 231CM Inc., Annual General Meeting, Jun 16, 20251CM Inc., Annual General Meeting, Jun 16, 2025. Location: ontario, toronto Canada
お知らせ • Sep 261Cm Inc. Expands its Operations Adding Tobacco, CPG, Private Label Products1CM Inc. announce the addition of Tobacco, Vape & Consumer Packaged Goods products to its retail portfolio. 1CM has begun retailing cigarettes and vape products as an authorized retailer of Imperial Tobacco Canada Ltd. A wholly owned subsidiary of British American Tobacco and Rothmans Benson & Hedges Inc. A wholly owned subsidiary of Altria (formerly Philip Morris International). These products are purchased directly from the manufacturers. 1CM has further begun retailing complimentary CPG products from Pepsi, Frito-Lay, Parmalat & Canada Bread. The products are distributed to the company from Arctic Beverages. 1CM has also begun producing its private label Vodka and Vodka Iced Tea. Under the brand "EPIC MILFF". These products are manufactured in collaboration with Minhas Sask Ventures Inc. This strategic horizontal expansion marks a significant milestone for the 1CM as it now extends its operations to Tobacco, CPG and Private Label products. 1CM will continue to leverage its technology to warehouse, mine and obtain insights from the valuable data obtained from its retail customers of Cannabis, Liquor, Tobacco, & CPG products. This data will allow the company to determine channel complementarity and provide unique cross-channel marketing opportunities and experiences to the age-gated 1CM customers. In industries like Tobacco and Cannabis with strict regulations around marketing, this provides an invaluable resource to 1CM and the tobacco industry as they will have a compliant marketing opportunity, supported by high quality data on purchasing patterns across multiple channels. 1CM is building a reputation in the liquor retail industry for its commitment to exceptional customer service, and value. These new product offerings will improve the customer experience and increase revenues.
お知らせ • Aug 011CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million.1CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million on December 1, 2022.1CM Inc. (CNSX:EPIC) completed the acquisition of Fresh Cannabis Co. Inc. from Cost Cannabis Inc. on December 1, 2022.
Board Change • Sep 15High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Lucas Leone is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jan 29First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.012 loss per share (down from CA$0.011 loss in 1Q 2021). Revenue: CA$228.1k (up 313% from 1Q 2021). Net loss: CA$991.0k (loss widened 10% from 1Q 2021). Revenue was in line with analyst estimates.
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Is New 90 Day High Low • Mar 06New 90-day high: €0.37The company is up 215% from its price of €0.12 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Feb 11New 90-day high: €0.35The company is up 249% from its price of €0.099 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 22New 90-day high: €0.22The company is up 136% from its price of €0.095 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period.